Patients diagnosed with lung squamous cell carcinoma (LUSC) have limited targeted 26 therapeutic options. We report here the identification and characterisation of the 27 transcriptional regulator, BCL11A, as a LUSC oncogene. Analysis of cancer genomics 28 datasets revealed BCL11A to be upregulated in LUSC but not lung adenocarcinoma 29 (LUAD). We demonstrated that knockdown of BCL11A in LUSC cell lines abolished 30 xenograft tumour growth and its overexpression in vivo led to lung airway hyperplasia 31 and the development of reserve cell hyperplastic lesions. In addition, deletion of Bcl11a 32 in the tracheal basal cells abolished the development of tracheosphere organoids while 33 its overexpression led to solid tracheospheres with a squamous phenotype. At the 34 molecular level we found BCL11A to be a target of SOX2 and we show that it is 35 required for the oncogenic role of SOX2 in LUSC. Furthermore, we showed that 36 BCL11A and SOX2 interact at the protein level and that together they co-regulated the 37 expression of several transcription factors. We demonstrate that pharmacological 38 inhibition of SETD8, a gene co-regulated by BCL11A and SOX2, alone or in 39 combination with cisplatin treatment, shows significant selectivity to LUSC in 40 comparison to LUAD cells. Collectively, these results indicate that the disruption of the 41 BCL11A-SOX2 transcriptional program provides a future framework for the 42 development of targeted therapeutic intervention for LUSC patients. 43 44 45 3 Main 46 Lung cancer accounts for the highest rate of cancer related diagnosis and mortality 47 worldwide 1 . Broadly, there are two major types of lung cancer; small cell lung cancer 48 (SCLC) accounting for 15% of the cases and non-small cell lung cancer (NSCLC) 49 accounting for 85% of cases 1 . NSCLC patients have a poor outcome in the clinic with 50 only 15% of patients surviving five years or more 2 . At present NSCLC is defined histo-51 pathologically in the clinic into four broad categories: lung adenocarcinoma (LUAD), 52 lung squamous cell carcinoma (LUSC), large cell carcinoma and undifferentiated non-53 small cell lung cancer. LUAD and LUSC are the most common types of NSCLC (90% 54 of cases). LUSC accounts for more than 400,000 deaths worldwide each year 3 and 55 unlike LUAD there are limited targeted therapies available for LUSC. Platinum-based 56 chemotherapy remains the first-line treatment for LUSC and although the recent FDA 57 approval of Necitumumab in combination with platinum-based chemotherapy for 58 metastatic LUSC has shown positive signs, a great deal of work still needs to be done in 59 this field 4 . 60 61
staining of NSCLC tumours 18 . This confirms our transcriptomic analyses indicating the 95 specificity of BCL11A in LUSC patients. 96 To determine if high levels of BCL11A expression are oncogenic in LUSC, we 97 performed shRNA mediated knockdown (KD) of BCL11A using two independent 98 shRNAs in two LUSC cell lines, LK2 and H520 ( Supplementary Fig. 2a and b ). We 99 first tested the clonogenic capacity of control or BCL11A-KD cells by seeding them into analysis revealed a significant decrease in organoid numbers from Bcl11a cko BCs but no 144 significant difference in BCL11A ovx BCs ( Supplementary Figure 4c Given the importance of SOX2 in driving LUSC 8,9 we next investigated if BCL11A is 154 regulated by SOX2. To achieve this, we knocked down SOX2 (SOX2-KD) in two LUSC To understand how BCL11A and SOX2 contribute to the LUSC transcriptional 170 programme we performed BCL11A and SOX2 ChIP-Seq analysis on LK2 cells in the 171 presence or absence of BCL11A (BCL11A-KD) (Figure 3i ). We identified 49,575 peaks 172 for SOX2 and 4,904 peaks for BCL11A (Figure 3j and Supplementary Tables 1 and 2) . 173 Out of the 4,904 BCL11A peaks identified, 3,941 were not present in BCL11A-KD cells 174 validating the true nature of BCL11A binding at these regions of the genome. We then compared the BCL11A peaks and the SOX2 peaks and identified 958 peaks, 177 which overlap suggesting co-regulation of these genes (Figure 3i and j). Subsequently, 178 we identified the nearest genes to the common peaks ( Supplementary Table 3 ) and 179 performed Gene Ontology (GO) analysis to identify if these common peaks are enriched 180 for specific biological process ( Figure 3j ). The top hits from the GO analysis revealed 181 enrichment for transcriptional and epigenetic regulators including SETD8, SKIL, and 182 TBX2 (Figure 3k ). We also found that SOX2 binds the BCL11A locus at multiple sites 183 suggesting a strong direct regulation at the transcriptional level further supporting the 184 data in Figure 3c and d (Figure 3k ). BCL11A and SOX2 peaks on SETD8 22,23 , SKIL 24 , 185 TBX2 25 and BCL11A were validated and confirmed by ChIP-qPCR (Supplementary 186 Figure 9 ). The overlap of the ChIP-Seq peaks suggests a direct interaction between 187 BCL11A and SOX2 proteins, which was confirmed in co-immunoprecipitation 188 experiments on LK2 and H520 ( Supplementary Figure 10a, b ).
190
We then investigated the expression of SETD8, SKIL and TBX2 in BCL11A-KD or 191 SOX2-KD cells. Interestingly, we found a modest reduction in the expression of these 192 genes in BCL11A-KD, which was more pronounced in SOX2-KD cells (Figure 4a We first assessed the expression of SETD8 in multiple NSCLC cell lines and found that In summary, we have demonstrated in this study that BCL11A is a LUSC oncogene. 226 We have shown that BCL11A is a key target of SOX2 and together they co-regulate the 227 expression of epigenetic regulators in LUSC cells. Our data suggests that disrupting the The control or the BCL11A overexpression piggybac vectors were delivered into 459 NSCLC cells using Lipofectamine LTX (Invitrogen). Transfected cells were maintained 460 for 48 hours and then cultured in puromycin (1µg/ml). To induce BCL11A expression 461 in LK2 SOX2-KD cells, doxycycline (Clonetech) was used at a final concentration of (1 462 µg/ml). 3D colony assays were performed by suspending 500 cells in matrigel (BD 463 Biosciences) and seeding this cell-matrigel suspension onto a 6-well plate. The plate 464 was then incubated for 15 minutes in 37 o C/5% CO 2 to allow hardening of suspension.
465
Growth media was added to the well and changed every 2-3 days for 20 days. All 466 experiments were performed in triplicates. can be found in Supplementary Table 5 and 6. The enrichment was normalised with 488 control mRNA levels of GAPDH and relative mRNA levels were calculated using the 489 ΔΔCt method comparing to control group. Supplementary Table 7 . The TCGA data was accessed from the recount2 database 40 containing gene level count 584 data from RNA-seq and clinical data from primary tumor samples from patients 585 diagnosed with LUAD and LUSC, respectively. EdgeR 41 was used to test for 586 differential expression of transcription factors (as defined by Tfcheckpoint.org). For 587 this, compositional differences between samples were normalized using the trimmed 588 median of M-values method and a gene-specific dispersion was estimated for each gene.
589
A negative binomial generalized log-linear model was fit to each gene with the 590 covariates "plate+disease_type" (for the LUAD versus LUSC comparison) or 
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